Table 5.
Uni- and multivariate analyses of factors affecting overall survival
| Variable | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | ||
| SMI | 1: high | ||||
| 2: low | 2.218 (1.106–4.449) | 0.025 | 2.246 (1.091–4.623) | 0.028 | |
| Age, years | 1: <75 | ||||
| 2: ≥75 | 1.046 (0.537–2.035) | 0.896 | |||
| Male sex | 1: − | ||||
| 2: + | 1.400 (0.722–2.715) | ||||
| BW, kg | 1: <60 | 1.477 (0.792–2.755) | 0.220 | ||
| 2: ≥60 | |||||
| BCLC stage | 1: B | ||||
| 2: C | 1.741 (0.916–3.306) | 0.090 | |||
| BCAA supplementation | 1: − | 1.235 (0.544–2.800) | 0.614 | ||
| 2: + | |||||
| Previous therapy: transcatheter treatment | 1: − | ||||
| 2: + | 1.308 (0.548–3.124) | 0.546 | |||
| Previous therapy: molecularly targeted therapy | 1: − | ||||
| 2: + | 1.543 (0.784–3.037) | 0.209 | |||
| Refractory to transcatheter treatment | 1: − | ||||
| 2: + | 1.224 (0.657–2.280) | 0.524 | |||
| Alpha-fetoprotein, ng/mL | 1: <200 | ||||
| 2: ≥200 | 2.193 (1.161–4.142) | 0.016 | 2.335 (1.210–4.507) | 0.011 | |
| ALBI score | 1: ≤-2.60 | 2.820 (1.293–6.154) | 0.009 | 4.636 (1.086–5.837) | 0.031 |
| 2: ≤-1.39 | 3.418 (1.425–8.198) | 0.006 | |||
| 3: >-1.39 | |||||
ALBI, albumin-bilirubin; BCAA, branched-chain amino acid; BCLC, Barcelona Clinic Liver Cancer; BW, body weight; CI, confidence interval; OR, odds ratio; SMI, skeletal muscle index.